Skip to content

Evaluate the Feasibility of Tricogs Tricare Platform.

GOALS-HF: GDMT OPTIMIZATION AND ADHERENCE LONGITUDINAL STUDY FOR HEART FAILURE - GOALS-HF

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053977
Enrollment
100
Registered
2023-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I509- Heart failure, unspecified

Interventions

Intervention1: NA: NA

Sponsors

TRICOG HEALTH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age = 18 years 2. Recent hospitalization (within 4 weeks of enrollment) for HF with IV diuretic use 3. Echocardiography data with EF measurements available in the last 6 months and after HF diagnosis 4. Established outpatient care at the participating sites 5. Eligible to receive at least 2 of the 4 GDMT classes (ACEi/ARB/ARNi, Beta-blockers, MRA, and SGLT2i) for HFrEF and at least one of the three (ARB/ARNI, MRA, SGLT2i) for HFpEF 6. Not on Target GDMT for all of the eligible GDMT classes 7. >12 months of expected survival 8. Comfortable with spoken and written English communication

Exclusion criteria

Exclusion criteria: 1. Under consideration for or recipient of advanced heart failure therapies (LVAD, Transplant) 2. Current or anticipated use of home intravenous inotrope therapy. 3. Unwilling or unable to perform all study related procedures (wear watch, take measurements and maintain daily logs) 4. Post-discharge placement in nursing, rehabilitation, or long-term care facility 5. Planned (within next 6 months) surgery 6. Inability to provide written consent

Design outcomes

Primary

MeasureTime frame
Multiple exploratory outcomes will be assessed. 1. HF-Collaboratory Score assessed at the beginning and end of the study. 2. Proportion of patients with HFpEF on MRA, and SGLT2i 3. Proportion of patients with (CHADS2VASC 2) with Atrial fibrillation on anticoagulation. 4. Changes in NT-proBNP, and KCCQ throughout the study period.Timepoint: 24 Weeks

Secondary

MeasureTime frame
1 HF-Collaboratory Score assessed at the beginning and end of the study 2 Proportion of patients with HFpEF on MRA and SGLT2i 3 Proportion of patients with CHADS2VASC greater than 2 with Atrial fibrillation on anticoagulation 4 Changes in NT proBNP and KCCQ throughout the study periodTimepoint: As per study protocol.

Countries

India

Contacts

Public ContactPerminder Singh

Manipal Hospital

drdschadha@gmail.com8390963737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026